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Abstract 
We demonstrate the use of electronic records and repeated 
measures of risk factors therein, to enable deeper 
understanding of the relationship between the full longitudinal 
trajectory of risk factors and outcomes. To illustrate, dynamic 
mixed effect modelling is used to summarise the level, trend 
and monitoring intensity of kidney function. The output from 
this model then forms covariates for a recurrent event Cox 
proportional hazards model for predicting adverse events (AE). 
Using data from Salford, UK, our multivariate model finds that 
steeper declines in kidney function raise the hazard of AE (HR: 
1.13, 95% CI (1.05, 1.22)).   There is a non-proportional 
relationship between the hazard of AE and the monitoring 
intensity of kidney function. Neither of these variables would be 
present in a classical risk prediction model.. This work 
illustrates the potential of using the full longitudinal profile of 
risk factors, rather than just their level. There is an opportunity 
for deep statistical learning leading to rich clinical insight 
using longitudinal signals in electronic data. 
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Introduction 
Most risk prediction models incorporate only the most recently 
measured value of a biomarker or risk factor. This is often in-
adequate as risk may be driven by decline, variability, or other 
complex aspects of the longitudinal trajectory. Electronic 
medical records contain rich longitudinal data from which risk 
factor trajectories can be estimated, and therefore used to en-
rich prediction models. In this paper we present an example of 
a two-stage model that first estimates the longitudinal trajec-
tory of a risk factor, then uses predictors derived from this in a 
risk prediction model. 
We illustrate the model using the example risk factor of esti-
mated glomerular filtration rate (eGFR), which is a measure of 
kidney function. Deteriorating kidney function is an important 
risk factor for adverse events. Chronic heart failure (CHF) and 
type 2 diabetes (T2DM) both damage the kidneys. CHF re-
duces blood flow through the kidneys due to weaker heart 
pumping; the factors causing it also affect the kidney blood 
vessels; and some CHF treatments may damage the kidney. 
T2DM damages the blood vessels and other parts of the kidney 
directly. So, patients with these conditions require particularly 
diligent monitoring of their regular laboratory test results. 
Kidney disease in patients with T2DM is well documented in 
the literature. A recent study in the US showed that as many as 
43.5% of patients with T2DM have chronic kidney disease 
(CKD) [1]; CKD is strongly associated with increased mortal-
ity and accelerated cardiovascular disease [2]. Patients with 
T2DM are also more likely to experience acute renal failure 
than patients without diabetes (adjusted hazard ratio: 2.5, 95% 
CI 2.2 – 2.7) [3]. Like CKD, acute renal failure is also associ-
ated with high mortality rate, around 50% [4]. 
Data from the EuroHeart Failure survey suggest that patients 
with T2DM and impaired kidney function have amongst the 
worst short and long-term outcomes [5]. A recent study [6], 
showed that the combination of poor heart and kidney function 
is a particularly strong and discrete risk factor for death. An-
other study [7] found that T2DM was a statistically significant 
predictor of all-cause mortality in patients with CHF, but only 
those who had eGFR between 30 and 90 ml/min*1.73m
2. Heart 
and kidney dysfunction are closely linked [8] and diabetes 
worsens the situation, whether measured by hospital admis-
sions or death rates [9]. 
In addition to slowly progressing disease, the kidneys can suf-
fer acute injury leading to emergency hospitalisation and death, 
especially among patients with CHF and T2DM. Most reported 
studies in this area have focused on measuring kidney function 
at the time of endpoints such as death or admission. This study 
shifts the focus to the process of deteriorating kidney function 
itself. The aim is to examine in detail the trajectory of eGFR 
prior to endpoints being observed. In particular we will con-
sider the effects of eGFR level, rate of decline and intensity of 
monitoring on adverse events such as emergency hospitalisa-
tion rates and all-cause mortality in patients with CHF and 
T2DM.  
Methods 
The data used in this study were obtained from the Salford In-
tegrated Record (SIR) – a medical data store in Salford, 
Greater Manchester, UK. The population of Salford is around 
234 thousand with 53 general practices and a single hospital. 
SIR contains linked data from both primary and secondary care 
for the population that engage with health services. 
The cohort was restricted to patients who had both CHF and 
T2DM. Patients with congenital heart disease and those with 
cor pulmonale were excluded from the study, as were patients 
who had renal replacement therapy during the study period, 
where eGFR has a different interpretation. The study period 
spanned from January 2008 to August 2012. 
The main outcome of interest was adverse events (AE), which 
comprise emergency hospital admissions and all-cause mortal-
ity. The covariates of primary interest were eGFR level, rate of 
decline and intensity of monitoring. Models were corrected for 
patient’s age at the time of follow-up start, gender, and index 
of multiple deprivation (IMD) 2010. All covariates related to 
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eGFR are time dependent and as such require estimation of the 
longitudinal process for each patient. Therefore we take a two 
stage modelling approach. In Stage 1, the eGFR process is es-
timated. Stage 2 then models AEs as a function of the eGFR 
process. 
For Stage 1, a simple approach to estimating the eGFR level at 
any time, t, is to use either the most recent eGFR value or some 
summary of a collection of recent eGFR values like the median 
or the mean. The eGFR decline can be calculated as the differ-
ence between the last and the penultimate eGFR values. In both 
cases, one needs to make several, rather arbitrary, decisions, 
for example, decide how far apart the two eGFR values should 
be in the case of calculating the eGFR decline. Also, as eGFR 
values can be ‘noisy’, this approach can be affected by varia-
tions in eGFR values. In order to smooth the variation in eGFR 
values and use all of the information about the degradation 
process of the kidney function in this particular population, we 
used dynamic mixed effects regression [10-11]. The eGFR 
level and decline for each patient at any given point in time , 
was derived from a mixed effects model fitted to all of the 
eGFR data prior to . The generic model was formulated as 
follows: dependent variable – the  logarithm of eGFR, predic-
tors (fixed effects) – age, gender, IMD, time since diagnosis 
(TSD) and time since study start (TSS), and random effects – 
variance of random effects on the intercept and coefficient of 
TSS. 
For each patient at each endpoint at time t, eGFR level was 
measured by the predicted eGFR value at time t and eGFR de-
cline was measured as    / 	   	

, where a is the predicted 
eGFR value at the start of the study, 	

, and b is the predicted 
eGFR value at time t. Since the kidney function for the cohort 




the eGFR slope is a positive number, where higher values indi-
cate steeper decline. 
The eGFR intensity of monitoring was measured as the prox-
imity of the most recent eGFR record: within 180 days, be-
tween 180 and 365 days and more than 365 days. 
For Stage 2, modelling the risk of AE, we used a repeated 
measures Cox proportional hazards (CPH) model with gamma 
shared frailty – i.e. patient level random effects were modelled 
using a gamma distribution [12]. CPH model is a popular 
method used to model survival data [13-14]. It is a semi-
parametric method with an advantage over parametric methods 
in that it focuses on hazard ratios only, thus, bypassing the 
need to specify a parametric distribution for the baseline haz-
ard. This allows direct comparison of the risk between subjects 
with different characteristics, where a hazard ratio of one indi-
cates that there is no difference in risk; ratios above one indi-
cate higher risk; and below one lower risk.      
Results 
The process of deriving the cohort is illustrated in Figure 1. 
Stage 1 
Table 1 shows exponentiated fixed effects of two log eGFR 
mixed effects models. The first model is the model fitted for 
the first AE during the study period. It is the model that used 
the smallest number of eGFR records for estimating the kidney 
function decline process. For each subsequent event, this model 
was updated with more data until the last model, which was 
fitted at the end of the study. Time is measured in years. From 
Table 1 we can note that older patients tend to have lower 
eGFR, female patients have lower eGFR than male patients,  
 
Figure 1 – Exclusion flowchart. 
patients who have had both CHF and T2DM for longer have 
lower eGFR, and the eGFR is in decline with time. 
Figure 2 shows the random effects of each patient on the inter-
cept and the coefficient of the TSS for the last model. For the 
intercept, patients with negative random effects have lower 
than average eGFR. For the slope, patients with negative ran-
dom effects have steeper than average decline in eGFR. We 
can see from Figure 2 that most of the steeper decline in eGFR 
is associated with patients with below average eGFR. The pre-
dicted eGFR levels and declines where carried forward to 
Stage 2. 
Table 1 – Exponentiated parameter estimates of log eGFR 
models. Interpretation example: male coefficient is greater 
than one, meaning male eGFR is predicted to be higher. 





(126.47, 168.56) a 
Age 0.99 (0.99, 0.99) a 0.99 (0.99, 0.99) a 
Gender:   
Female 1 1 
Male 1.07 (1.03, 1.11) a 1.05 (1.01, 1.1) a 
Time since  
diagnosis 
0.98 (0.98, 0.99) a 0.98 (0.98, 0.99) a 
Time since  
study start  0.96 (0.95, 0.98) a 0.97 (0.97, 0.98) a 
Key: a – statistically significant at 5% 
 
  
A. Akbarov et al. / A Two-Stage Dynamic Model to Enable Updating of Clinical Risk Prediction 697
 Figure 2 – Patient random effects on the intercept and on the slope of time since study start [15].  
 
Stage 2  
Table 2 shows covariate details and hazard ratios for univariate 
and multivariate models for AE. We can note the following 
from the table. Older patients are at higher risk of AE. Gender, 
IMD and eGFR level were not statistically significant, whereas 
the eGFR decline was. The hazard ratio for the eGFR decline 
indicates that a one unit decrease in eGFR per year increases 
the hazard of AE by 10-11%. The hazard ratios for the eGFR 
monitoring indicate that patients with more recent eGFR re-
cords are more likely to have AE. The multivariate model was 
selected on the basis of significance of the parameter estimates. 
The eGFR monitoring covariate failed to adhere to the propor-
tional hazards assumption, so the multivariate model is strati-
fied on this. Kaplan-Meier plots of the eGFR monitoring strata 
are presented in Figure 3.  
 
Figure 3 – Kaplan Meier plot of AE-free survival stratified by 
time since most recent eGFR measurement. 
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Table 2 – Hazard ratios for emergency hospital admissions models. Hazard ratios greater than one represent higher risk. 
Covariates 
Mean (SD), count 
or proportion 
Hazard ratio (95% CI) 
  Univariate Multivariate 
Age 73.03 (10.43) 1.02 (1.01, 1.04)
a 1.03 (1.01, 1.05)a 
Gender:    
Female 42% 1 (reference) - 
Male 58% 1.2 (0.857, 1.68) - 
IMD 2010 37.16 (18.20) 1 (0.993, 1.01) - 
eGFR level 59.03 (18.18) 0.996 (0.988, 1) - 
eGFR decline 2.27 (2.05) 1.11 (1.03, 1.19)
a 1.13 (1.05, 1.22)a 
Last eGFR 58.58 (21.37) 0.993 (0.986, 1)
a - 
eGFR monitoring:    
[1, 180] 730 1 - 
(180, 365] 149 0.21 (0.12, 0.35)
a - 
> 365 190 0.13 (0.08, 0.20)
a - 
Key: a – statistically significant at 5% 
 
Discussion 
We have presented a proof-of-concept study of a two-stage 
framework for modelling the full longitudinal profile of a risk 
factor and its impact on risk, using the example of eGFR de-
cline in T2DM and CHF patients. We found that eGFR decline, 
modelled as patient-specific slope from a mixed effects model, 
was a strong predictor for adverse events (AE), and eGFR level 
was not a significant predictor either in a univariate or multi-
variate model. In a standard predictive modelling framework, 
only the most recent eGFR measurement would have been 
taken, so eGFR decline would not have been captured. We ad-
ditionally considered the intensity of eGFR measurement as a 
predictor, and found a complex relationship between this and 
AE. 
The main strength of this study is the incorporation of longitu-
dinal information from routine care-records into risk predic-
tion, a feature absent from standard models. We considered one 
risk factor but the method is easily extended to multiple risk 
factors. The main weakness is that uncertainty in eGFR predic-
tions is not propagated to the estimates of the hazard ratios 
across the two stages of the method. Future work will investi-
gate joint modelling approaches to overcome this. 
We considered only mixed effects regression to model the tra-
jectory of eGFR. Other methods such as random forests, neural 
networks and support vector regression could be used for this 
purpose. These machine-learning techniques might better cope 
with additional covariates, particularly treatments for T2DM 
and CHF that could influence kidney function. In our data, 
there were over a thousand different medications prescribed 
among our patient cohort in the month preceding the first 
eGFR measurement. Future work will compare alternative dy-
namic modelling strategies capable of incorporating complex 
covariate structures. 
The ability to monitor and predict longitudinal processes using 
dynamic models, integrated with medical records, provides an 
opportunity to develop optimal monitoring polices for these 
risk factors. Linking the predictions of the kidney function de-
cline to the effectiveness of its monitoring, aimed at averting 
adverse events, is a hard problem and the subject of ongoing 
research. This requires investigating the mechanism behind 
how the decline in eGFR leads to adverse events. For example, 
it may be that the decline in eGFR first leads to changes in 
treatment that in turn precipitate adverse events. 
As with most routine care-records, the data in our study had 
limitations. In particular, the linkage of emergency hospital 
admissions to the SIR database required general practitioners to 
enter or accept data on admission episodes. In addition, we did 
not have data on the duration of hospital admissions, which 
could have been used to refine our endpoint definitions. 
Despite limitations in the data and methodology this study has 
clearly demonstrated that clinical predictive models can im-
prove their predictive abilities by taking account of the longi-
tudinal information in electronic health records. 
Consider EU Directive 2007/47 that considers algorithms used 
for prognostic purposes to be “medical devices.” The usual 
validation methods for such algorithms certify the encoding 
into software of models, but rarely question the fact that pub-
lished model parameters will drift in calibration as risk-factor 
environments change. In addition, the structure of models may 
need reconsidering as populations, contexts of health-
care/observation and data-quality evolve. 
Conclusion 
Sophisticated statistical modelling with electronic health re-
cords allows for complex relationships between risk factor tra-
jectories and outcomes to be captured, thereby improving pre-
dictions. Most current predictive models do not exploit longi-
tudinal health record information in this way – neither is the 
regulatory framework for clinical algorithms set up to cope 
with this dynamic modelling approach. Research is urgently 
needed into statistical methods and computational frameworks 
for optimising clinical prediction from the continuously evolv-
ing risk information across heterogeneous populations, health-
care environments and information systems. 
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